Table 3 Base case results (per patient)
NAT | Tolvaptan | Incremental | |
|---|---|---|---|
General SIADH | |||
Total costs | SEK 45,462 | SEK 39,683 | -SEK 5,779 |
QALYs | 0.05381 | 0.05567 | 0.00186 |
ICER | Tolvaptan dominates | ||
SCLC | |||
Total costs | SEK 372,717 | SEK 364,306 | -SEK 8,411 |
QALYs | 0.21817 | 0.22101 | 0.00284 |
ICER | Tolvaptan dominates | ||
Pneumonia | |||
Total costs | SEK 26,541 | SEK 23,863 | -SEK 2,678 |
QALYs | 0.05689 | 0.05868 | 0.00179 |
ICER | Tolvaptan dominates | ||